---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-008037"
form_type: "8-K"
ticker: "RGNX"
cik: "0001590877"
company_name: "REGENXBIO Inc."
filed_at: "2022-03-01T23:59:59+00:00"
generated_at: "2026-06-27T03:01:04.232629+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# REGENXBIO reports Q4 net income $294M on AbbVie deal; cash $849M into 2025

## Summary
- Q4 2021 net income $294M ($6.87 basic EPS) vs net loss $46.2M in Q4 2020; revenue $398.7M (incl $370M AbbVie upfront).
- Cash, equivalents & marketable securities $849.3M at Dec 31, 2021; runway into 2025.
- Closed eye care collaboration with AbbVie: $370M upfront + up to $1.38B milestones; two pivotal trials (ATMOSPHERE, ASCENT) for wet AMD.
- RGX-202: FDA cleared IND, granted Rare Pediatric Disease & Orphan Drug designations; Phase I/II AFFINITY DUCHENNE trial to start H1 2022.
- RGX-314 suprachoroidal: Phase II AAVIATE (wet AMD) & ALTITUDE (DR) show reduced treatment burden; enrollment in higher-dose cohorts ongoing.

## SEC filing metadata
- accession: 0001564590-22-008037
- form_type: 8-K
- ticker: RGNX
- cik: 0001590877
- company_name: REGENXBIO Inc.
- filed_at: 2022-03-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590877/000156459022008037/0001564590-22-008037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590877/000156459022008037/rgnx-8k_20220301.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-008037
- JSON: https://secwatch.observer/filing/0001564590-22-008037.json
- Plain text: https://secwatch.observer/filing/0001564590-22-008037.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.